Here, we publish important new scientific research and materials, discuss significant NGP category developments in the media, report on scientific conferences we’ve attended, and more. Please note not all of this content is available in certain territories.
NEW HUMAN CLINICAL DATA DEMONSTRATES RAPID AND SIGNIFICANT REDUCTIONS IN SELECT DISEASE-RELATED BIOMARKERS OF EXPOSURE TO HARMFUL CHEMICALS WHEN ADULT SMOKERS EITHER FULLY OR PARTIALLY TRANSITION TO VAPING, AS WELL AS DRAMATIC REVERSALS OF THESE RESULTS IF SMOKING IS RESUMED. Vaping offers adult smokers a potentially harm reduced method of nicotine delivery. A comprehensive, rolling […]
7 Jun 2022
New clinical data re-affirms nicotine salt-derived e-liquids more closely resemble the smoking experience than their freebase equivalents Innovative new research by Imperial Brands Science in partnership with Uppsala University, Sweden published in the peer-reviewed journal Pharmaceuticals has investigated the distribution and deposition of inhaled nicotine when adult smokers vape myblu using two distinct nicotine e-liquid […]
23 May 2022
We’ve developed our new relative risk scale to visually represent what the science currently says about the potential risks between the various nicotine product categories. Head of Harm Reduction and Engagement Grant O’Connell explains more. Given the wide range of nicotine-containing products now available, we believe it’s important policy makers, media, regulators and – most […]
13 May 2022
Imperial Brands has conducted a clinical assessment of its tobacco-free nicotine pouch products. Clinical Research Senior Manager Simon McDermott presents a summary of the data Among the Next Generation Products (NGPs) with the potential to make a meaningful contribution to the public health concept of tobacco harm reduction (THR) are tobacco-free oral nicotine pouches. Free […]
9 May 2022
Reduced levels of toxicants in Imperial Brands nicotine pouches translates directly into substantially reduced in-vitro biological activity in recent study As part of our commitment to making a meaningful contribution to tobacco harm reduction (THR), Imperial Brands continues to assess the THR potential of our Next Generation Product (NGP) portfolio relative to combustible tobacco. In […]
8 Mar 2022
Pre-clinical assessment using rapid screening Cardio quickPredict assay further substantiates potentially harm reduced alternatives to combustible cigarettes in recent study The smoking of combustible cigarettes has an established association with cardiovascular disease. As part of our commitment to making a meaningful contribution to tobacco harm reduction, Imperial Brands recently evaluated the cardiotoxicity potential of our […]
18 Feb 2022
